Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Biocomposites exceeds revenue expectations and takes a big step forward in its research and development


News provided by

Biocomposites

13 Dec, 2023, 08:30 GMT

Share this article

Share toX

Share this article

Share toX

  • New record for sales growth and number of patients supported
  • Product portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infection
  • Research and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in Renovite

KEELE, England, Dec. 13, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, reports a year of record growth, investment in new products and breakthroughs in research and development.

Helping more patients

2023 was a new record for the number of patients benefiting from a Biocomposites product as part of their treatment plan. This was a result of over 30% growth in demand for our products in China, India, UK, Europe and across the Americas - driven by product performance as well as a broadening of adoption beyond the traditional specialty of orthopaedics into new areas such as spine, foot and ankle, and podiatry.

Biocomposites' extensive geographic footprint was also extended by the addition of new distributors in South Africa, Israel, Turkey, Greece, Cyprus, Singapore, Thailand, Dominican Republic, Venezuela and Guatemala. Subiton and Synimed products also started to be sold through the Biocomposites network in the UK and India.

Enhanced product portfolio

The acquisition of NanoBone technology, in June this year, added a new range of osteoinductive synthetic bone grafts to Biocomposites' portfolio. Its patented nanostructured hydroxyapatite platelets mimic the hydroxyapatite in natural bone and deliver a comparable healing rate to autograft, without the costs and complications of harvesting bone from a patient.

Great progress was also made in extending STIMULAN's approval throughout the world. It is still the only calcium matrix approved to assist in wound healing, treat bacterial infection and carry antibiotics in bone and soft tissue. Today, STIMULAN, when pre-mixed with antibiotics, can be used to treat bacterial infection in Canada, Colombia, Brazil, Mexico and South Africa. It can also be used to carry antibiotics in Argentina, Brunei, Chile, Costa Rica, Dominican Republic, Egypt, Europe, Guatemala, Hong Kong, Israel, Jamaica, Jordan, Kuwait, Malaysia, New Zealand, Panama, Puerto Rico, Qatar, Saudi Arabia, Serbia, Singapore, Taiwan, Thailand, Trinidad & Tobago, UK, and Vietnam.

R & D boost

This year, we took a big step forward in the development of STIMULAN VG, by gaining FDA approval to progress to a Phase II clinical trial. STIMULAN VG, which is STIMULAN mixed with vancomycin and gentamicin, will be a new drug-device combination that aims to treat diabetic foot osteomyelitis – with the potential to transform outcomes and positively impact many patients' lives.

Biocomposites also invested in Renovos, an innovative biologics company born out of research into the properties of nanoclay at the University of Southampton. Their novel therapeutic delivery platform, RENOVITE®, is a synthetic, biodegradable nanoclay carrier that can be used to place a wide range of pharmaceutical drugs and biologics at the site of treatment. As a cell-responsive carrier it requires a lower dose of therapeutic drug to accelerate healing. Together we are working through the regulatory pathway to bring their transformative products to market.

Strengthening the team

Biocomposites expanded its senior management team with the appointment of two new directors. In August 2023, Michelle Lewis became Human Resources Director, leading Biocomposites in managing its rapidly expanding workforce, which has doubled in the last two years. Ciara Airey became Regulatory Affairs Director, developing the team and framework to support the regulatory pathway of the company's extensive medical device and drug-device combination pipeline. These appointments reflect the company's strong growth and the need to manage an increasing talent pool of people, whilst maximising the opportunity to grow revenue through regulatory differentiation.

Biocomposites' team members attended and presented at a number of scientific and industry events and conferences throughout the year. In October 2023, Biocomposites hosted a symposium with two leading clinicians at the 41st Annual Meeting of the European Bone & Joint Infection Society (EBJIS) in Basel, Switzerland, and presented cutting-edge data demonstrating the benefits of STIMULAN in improving outcomes for periprosthetic joint infection patients.  Addressing specialties beyond orthopaedics, Biocomposites also sponsored a session at this year's Wounds UK Annual Conference held in Harrogate, UK, on 7 November 2023, at which a consensus group of multidisciplinary clinicians from leading research units discussed managing the complex foot infections associated with diabetes and the role STIMULAN plays in improving patient outcomes.

Commenting on Biocomposites' extraordinary year, Michael Harris, Chief Executive Officer, said: "Our 2023 performance has exceeded all our expectations. Our products make a real difference to people's lives and it is wonderful to see so many more patients benefiting from them. With the acceleration of research and product development over the last five years, we are now seeing tangible milestones achieved as we position ourselves as the go-to-provider for surgeons and podiatrists seeking to treat infected patients."

About Biocomposites

Biocomposites is an international medical devices company that engineers, manufactures, and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Argentina, Canada, China, and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in over one million procedures per annum and sold in more than 100 countries around the world. Please visit biocomposites.com to learn more.

Modal title

Also from this source

Biocomposites invests in InfectoTest GmbH - developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection...

Biocomposites to showcase innovations in infection management at EBJIS 2024

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.